Chinese regulators reviewing pair of BeiGene therapies

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) said Friday that China's National Medical Products Administration accepted an NDA for anti-PD-1 mAb tislelizumab (BGB-A317) to treat relapsed or refractory classical Hodgkin lymphoma (cHL).

The news follows BeiGene's Aug. 26 announcement that the agency is reviewing its zanubrutinib (BGB-3111), a selective oral Bruton's tyrosine kinase (Btk) inhibitor, to treat relapsed or refractory mantle cell lymphoma (MCL)...